What to Expect from Mounjaro After 4 Weeks

What the trial data actually show at this stage

The SURMOUNT-1 trial followed over 2,500 adults with obesity over 72 weeks, tracking weight loss at every dose level from 5mg through to 15mg. The trial's published results in the New England Journal of Medicine make clear that meaningful, consistent weight reduction developed across many months, not the first few weeks. Week four coincides almost exactly with the end of the 2.5mg starter phase for most patients, a dose whose purpose is tolerability, not peak efficacy. The body is learning to work with a dual GIP and GLP-1 receptor agonist for the first time, and that adjustment takes time.

Participants in SURMOUNT-1 who reached the 15mg maintenance dose lost an average of around 20% of their body weight by week 72. Patients on 10mg averaged roughly 15%, and even lower doses produced clinically significant losses. None of those outcomes were established by week four. The trajectory is long, and comparing your first month to someone else's six-month result is a comparison that will always look unfair.

If you are curious how the picture typically looks a little further along, what patients tend to notice by week six gives a more detailed breakdown of what the data shows once the first dose increase has had time to act.

Side effects are often front-loaded (here is why

A question our prescribers hear most weeks: "I feel sick every time I eat) does that mean it's working, or is something wrong?" The honest answer is: both things can be true at once. Gastrointestinal effects (nausea, changes in bowel habit, burping, a reduced appetite that sometimes tips into not wanting to eat at all) are most prominent during dose initiation and after each step up. For many people, week four lands right in the middle of that initial adjustment window.

The NHS medicines page for tirzepatide lists nausea, diarrhoea, vomiting, constipation and indigestion as the most commonly reported effects, and notes they typically ease as treatment continues. Slowing gastric emptying (part of how tirzepatide works) is the main driver, and the body usually adapts. Eating smaller portions, avoiding rich or fatty foods, and staying well hydrated all help; your prescriber and patient information leaflet are the right sources for personalised advice.

Side effects that are severe, persistent, or include intense stomach pain radiating to the back warrant prompt medical attention. The MHRA has highlighted acute pancreatitis as a known but infrequent serious effect of GLP-1 medicines, if that pattern of pain develops, seek help the same day rather than waiting for your next check-in.

Weight change at four weeks: realistic expectations by dose

Some people notice a real shift by week four. Others notice almost none. Both experiences are consistent with what the clinical data show. Weight loss at this stage is influenced by how much appetite suppression you are experiencing on 2.5mg, your starting calorie intake, activity levels, and individual variation in how quickly the medicine takes effect. The 2.5mg dose was not designed to be a long-term maintenance dose, it exists to reduce the likelihood of severe early side effects before the first increase.

For patients who began at a higher dose after transferring from another provider, or who are restarting Mounjaro after a gap, week four may look quite different. Those situations carry their own clinical considerations, and a prescriber should review progress rather than relying on general averages.

Cost context sometimes comes up at this stage, when people are weighing whether to continue. A factual overview of how Mounjaro is priced in the UK private market may help if you are assessing your options, though for a prescription medicine, the clinical relationship and supply-chain legitimacy matter at least as much as the monthly figure.

What to do if you feel nothing has changed

The most evidence-supported response to week four without visible change is patience, not panic. Tirzepatide's effects on appetite and weight compound over successive dose increases, and NICE's appraisal of tirzepatide (TA1026) explicitly notes that the medicine's effectiveness is assessed at six months on the highest tolerated dose, not at one month on the starter dose. That framing is deliberate.

Practically, week four is a good moment to take stock of the support structures around treatment: are you eating in a way that lets the appetite-suppressing effect work? Are you tracking any changes in hunger, portion size or food cravings, even if the scales have not moved much? Many people find those subtler shifts are the first real signal before weight follows. A detailed look at the four-week experience covers practical day-to-day questions, and if you want to understand how early progress can vary, reading about what the first three weeks on Mounjaro tend to involve helps put the timeline in context, while our tirzepatide overview sets out the full clinical picture if you want more background on how the medicine works across its full dose range.

If you have not yet started treatment and are considering whether Mounjaro is right for you, start a free consultation with one of our GPhC-registered prescribers. A real clinician reads every submission the same day, your history, your circumstances, your goals.